Cargando…
Lebrikizumab in the personalized management of asthma
There is a need for improved therapies for severe asthma. Lebrikizumab, a humanized monoclonal antibody that binds to interleukin (IL)-13, is under development for the treatment of poorly controlled asthma. This article reviews the potential role of IL-13 in the pathogenesis of asthma, the efficacy...
Autores principales: | Thomson, Neil C, Patel, Manish, Smith, Andrew D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459551/ https://www.ncbi.nlm.nih.gov/pubmed/23055690 http://dx.doi.org/10.2147/BTT.S28666 |
Ejemplares similares
-
Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015) -
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022) -
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
por: Szefler, Stanley J., et al.
Publicado: (2022) -
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020) -
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)